Short‑term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)

Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

大型3型/4型胃癌に対する術前S-1+Oxaliplatin+ Docetaxel併用療法の有効性と安全性確認第II相試験(OGSG1902)短期成績報告

高度リンパ節転移を伴う進行胃癌に対する周術期 Capecitabine＋Oxaliplatin療法の第II相試験（OGSG1701）

RINDBeRG試験におけるラムシルマブの投与タイミングにおけるサブグループ解析

Effects of an oral elemental nutritional supplement for gastric cancer with adjuvant S-1 therapy（Phase II trial: OGSG1108）

Phase I study of neoadjuvant chemoradiotherapy with S‑1 for clinicallyresectable type 4 or large type 3 gastric cancer in elderly patients aged75 years and older (OGSG1303)

Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)

Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S‑1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)